← Back
January 10, 2019

Clinical Potential

In order to provide advice on the clinical potential for PharmNovo’s delta opioid receptor agonists, Professor Andrew Rice from Imperial College London has agreed to become a consultant to the team. Prof Rice is an internationally regarded clinical and scientific expert in the field of chronic pain.

Author:

Bengt von Mentzer

22 MSEK new funding

PharmNovo has completed a new share issue of 22 million SEK with the Sciety investment syndicate as the lead investor.

Read more →

Research coaction

As a result of our publication in JPET with University of Bristol, contact was established with Prof. Amynah Pradhan at the University of Illinois, Chicago.

Read more →

New CEO appointed

The board of PharmNovo AB is pleased to announce that former VP Business Development Per von Mentzer assumed the position as new Chief Executive Officer of PharmNovo AB effective May 2020.

Read more →

JPET approves PN6047

In collaboration with our research partners at the University of Bristol, we have had a manuscript detailing the results of our preclinical studies of PN6047 accepted for publication in the highly cited Journal of Experimental Pharmacology and Therapeutics (JPET), the official journal of the American Society for Pharmacology and Experimental Therapeutics (ASPET).

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map